Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

R. Suzuki, T. Hideshima, N. Mimura, J. Minami, H. Ohguchi, S. Kikuchi, Y. Yoshida, G. Gorgun, D. Cirstea, F. Cottini, J. Jakubikova, Y. T. Tai, D. Chauhan, P. G. Richardson, N. C. Munshi, T. Utsugi, K. C. Anderson

Research output: Contribution to journalArticle

18 Scopus citations
Original languageEnglish (US)
Pages (from-to)510-514
Number of pages5
JournalLeukemia
Volume29
Issue number2
DOIs
StatePublished - Feb 7 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Suzuki, R., Hideshima, T., Mimura, N., Minami, J., Ohguchi, H., Kikuchi, S., Yoshida, Y., Gorgun, G., Cirstea, D., Cottini, F., Jakubikova, J., Tai, Y. T., Chauhan, D., Richardson, P. G., Munshi, N. C., Utsugi, T., & Anderson, K. C. (2015). Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia, 29(2), 510-514. https://doi.org/10.1038/leu.2014.300